Analysts Impressed As Novo Nordisk’s PIONEER 6 Trial Confirms Safety Profile Of Oral Semaglutide

 
• By Sten Stovall

Oral semaglutide hit its main endpoint by demonstrating cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in the PIONEER 6 trial.

Heart
Trial is part of Novo Nordisk's PIONEER clinical development program • Source: Shutterstock

More from Alimentary/Metabolic

More from Therapy Areas